Patents by Inventor Robert L. Jerzewski

Robert L. Jerzewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170079999
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Terrence C. DAHL, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLIYAI, Taiyin YANG
  • Patent number: 9545414
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: January 17, 2017
    Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLC
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Publication number: 20150174147
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: March 6, 2015
    Publication date: June 25, 2015
    Inventors: Terrence C. Dahl, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLlYAI, Taiyin YANG
  • Patent number: 9018192
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Publication number: 20140037724
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLC
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Patent number: 8598185
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Publication number: 20040005358
    Abstract: A modified-release vasopeptidase inhibitor formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE inhibitory activity, in a balanced manner, for a predetermined duration to lower blood pressure and/or treat heart failure. In a preferred formulation, the NEP inhibitory activity and ACE inhibitory activity have balanced release characteristics.
    Type: Application
    Filed: April 21, 2003
    Publication date: January 8, 2004
    Inventors: Peter H. Slugg, Nemichand B. Jain, Rajesh Krishna, Robert L. Jerzewski, Ronald L. Smith, Jatin M. Patel, Bimal K. Malhotra
  • Patent number: 5506248
    Abstract: An ifetroban composition is provided which has good dissolution properties even on aging, when dispersed in water has a pH of at least 7 and includes a salt of ifetroban, one or more basifying agents, such as magnesium oxide or calcium carbonate, and where in tablet form includes one or more fillers such as mannitol and/or microcrystalline cellulose, one or more disintegrating agents such as crospovidone, one or more lubricants such as magnesium stearate, optionally one or more glidants such as colloidal silicon dioxide, one or more binders such as pregelatinized starch (dry binder) or polyvinyl-pyrrolidone (wet binder) and optionally a film coating containing a film former such as hydroxypropyl cellulose and a plasticizer such as 1,2,3-propanetriol triacetate.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 9, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Faranak Nikfar, Abu T. M. Serajuddin, Robert L. Jerzewski, Nemichand B. Jain
  • Patent number: 5006344
    Abstract: Shelf stable tablets containing fosinopril sodium are prepared by employing either sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant. The tablets can contain conventional excipients such as fillers, binders, and disintegrants as well as an optional diuretic.
    Type: Grant
    Filed: June 26, 1990
    Date of Patent: April 9, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert L. Jerzewski, Thomas M. Wong, Lewis J. Gryziewicz, Nemichand B. Jain, Ajit B. Thakur